The Hemorrhage drugs in development market research report provides comprehensive information on the therapeutics under development for Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemorrhage. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemorrhage and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Hemorrhage by 14 companies/universities/institutes. The top development phase for Hemorrhage is preclinical with five drugs in that stage. The Hemorrhage pipeline has 11 drugs in development by companies and four by universities/ institutes. Some of the companies in the Hemorrhage pipeline products market are: Coagulant Therapeutics, Cayuga Biotech and Monash University.
The key targets in the Hemorrhage pipeline products market include Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21), Prothrombin (Coagulation Factor II or F2 or EC 3.4.21.5), and Oxytocin Receptor (OTR or OXTR).
The key mechanisms of action in the Hemorrhage pipeline product include Coagulation Factor VII (Proconvertin or Serum Prothrombin Conversion Accelerator or SPCA or Eptacog Alfa or F7 or EC 3.4.21.21) Replacement with two drugs in Phase III. The Hemorrhage pipeline products include seven routes of administration with the top ROA being Intravenous and nine key molecule types in the Hemorrhage pipeline products market including Small Molecule, and Synthetic Peptide.
Hemorrhage overview
Hemorrhage refers to the loss of blood from damaged blood vessels. A hemorrhage may be internal or external, and usually involves a lot of bleeding in a short time. Symptoms include nausea or vomiting, difficulty swallowing, loss of coordination, loss of consciousness, severe headache, and tingling or numbness.
For a complete picture of Hemorrhage’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
